9713 Key West Ave., Suite 400
About MaxCyte, Inc.
We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and solve development and commercialization challenges.
This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance – facilitating rapid, large-scale, clinical- and commercial-grade cell-engineering in a non-viral system and with low-toxicity concerns. Our cell-engineering platform is FDA-cleared, providing our customers and partners with an established regulatory path to commercialize cell-based medicines.
We are also developing novel CARMA cellular therapies for our own pipeline with our first drug candidate in a Phase I clinical trial. CARMA is MaxCyte’s novel proprietary technology for development of human mRNA-based cellular therapies to treat a broad range of diseases.
Stock Exchange: Alternative Investment Market
Stock Symbol: MXCT
At MaxCyte, we take a collaborative partnering approach with our clients with the goal of rapidly driving our partners’ development efforts forward through to commercial use, more cost-effectively and with lowered risk. We have developed and commercialized MaxCyte Scalable Transfection Systems for high-performance delivery of biomolecules using Flow Electroporation ® Technology, a proprietary cell-engineering technology designed to meet the stringent demands of clinical use – namely, the ability to safely and reproducibly modify primary human cells with high efficiency, low cytotoxicity, and at the scale required to treat patients.
186 articles with MaxCyte, Inc.
The 2021 IPO stampede continues with five more companies aiming to trade on a stock exchange.
MaxCyte, a leading provider of platform technologies for cell engineering, announced the appointment of Rekha Hemrajani and Yasir Al-Wakeel, BM BCh, to the company's board of directors as non-executive directors with immediate effect.
Celularity and MaxCyte Sign Strategic Platform License to Advance Celularity's Off-the-shelf Allogeneic Cellular Therapy Product Candidates
Celularity to utilize MaxCyte's Flow Electroporation® technology and ExPERT™ platform to advance its off-the-shelf placental-derived allogeneic cellular therapies to treat hematological malignancies, solid tumors, and infectious and degenerative diseases
MaxCyte, Inc., a leading provider of platform technologies for cell engineering, announces that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market.
MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced two upcoming presentations at virtual healthcare investor conferences. Details are as follows.
MaxCyte, Inc., a global cell-based therapies and life sciences company, announces that CEO Doug Doerfler will present an overview of the company at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, and at the Jefferies Virtual London Healthcare Conference on Thursday, November 19.
CARMA Cell Therapies™ to Share Results of In-vitro Characterization of MCY-M11 at SITC 2020 Annual Meeting
MaxCyte, Inc., a global cell-based therapies and life sciences company, announces that its subsidiary CARMA Cell Therapies will share results of a detailed phenotypic and functional characterization of MCY-M11, its lead anti-mesothelin CAR-PBMC cell therapy candidate, at the Society for Immunotherapy of Cancer's (SITC) 35th anniversary meeting
10/16/2020Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.
MaxCyte Bolsters Leadership Team with Promotion of Brad Calvin to Chief Commercial Officer and New Key VP Appointments
MaxCyte, Inc., a global cell-based therapies and life sciences company, announces a senior leadership promotion and appointments for two key vice president roles.
MaxCyte to Present at Upcoming 2020 H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference
MaxCyte, a global cell-based therapies and life sciences company, today announced that CEO Doug Doerfler plans to present an overview of the company at the upcoming H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference taking place September 14-16 , 2020. Details are as follows:
MaxCyte Appoints Amanda L. Murphy as Chief Financial Officer and Names Ron Holtz as Senior Vice President & Chief Accounting Officer
Murphy brings a wealth of life sciences capital markets experience and deep knowledge in the enabling technologies and cell therapy sectors
New parallel cohort will broaden evaluation of MCY-M11 in patients through inclusion of a preconditioning regimen and multiple dosing cycles
APEIRON to utilize MaxCyte's ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials
MaxCyte® Initiates Launch of New ExPERT™ Range of Expanded Research and GMP Grade Disposables for Complex Cellular Engineering
Enhanced range of volumes and design features will support expanded use in both cell therapy drug development and early drug discovery
MaxCyte, a global cell-based therapies and life sciences company, announced that CEO Doug Doerfler plans to present an overview of the company and provide a business update at the 2020 European Biotech Investor Day, co-hosted by Solebury Trout with Nasdaq, Deutsche Bank and Goodwin.
MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announces that clinical data from the first three cohorts of the ongoing Phase I dose-escalation trial demonstrating safety of MCY-M11 and feasibility of one-day manufacturing will be shared at the American Society of Clinical Oncology's upcoming annual meeting.
- Agreement enables Caribou to utilize MaxCyte's ExPERT® platform for its CRISPR gene-edited, allogeneic T cell therapy programs
Dosing of fourth cohort initiated according to plan in Phase I clinical trial of lead CARMA therapy candidate, MCY-M11
BioSpace takes a quick look at some recent, key industry news that is not related to the coronavirus.
MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies
Agreement enables Allogene, a pioneer in the development of AlloCAR T™ therapies for cancer, to utilize MaxCyte's ExPERT™ platform in target candidates